pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ZEPBOUND · news · pharmadog
← back to ZEPBOUND
News mentioning ZEPBOUND
155
stories
4d
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
biopharma dive
6d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
6d
STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
stat
9d
STAT+: Up and down the ladder: The latest comings and goings
stat
9d
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
stat
9d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
10d
Deep dive: Cardiovascular calamities and catalysts
biospace
10d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
10d
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
stat
11d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
11d
STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
stat
11d
The U.S. may soon lose measles elimination status
stat
11d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
12d
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
stat
12d
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
stat
13d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
13d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
13d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
13d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
13d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
13d
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
stat
13d
Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...
raps
16d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
17d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
18d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
18d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
19d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
23d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
24d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
25d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
← prev
page 1 of 6
next →